KANDOVA - A Two-Part Phase Ib/IIa Study to Evaluate the Safety and Tolerability of KAND567, in Combination With Carboplatin Therapy, and to Determine the Recommended Phase II Dose (RPIID) of KAND567: An Open-Label, Multicenter Dose Escalation Study With an Expansion Cohort in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The study is a multicenter, Phase Ib/IIa, open-label, dose-escalation study to evaluate the safety and tolerability of orally administered KAND567 in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND567 in combination with carboplatin in subjects with recurrent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
In Part 1, dose escalation will be based on the recommendation of the Safety Review Committee (SRC) after review of the emerging safety and tolerability information. The SRC is also mandated to modify the dose levels within the dose range (125 to 625 mg BID), as well as the schedule to maintain subject safety and best serve the objectives of the study. Once the RPIID has been identified in Part 1, the SRC may recommend to the Sponsor to start Part 2.
An expansion cohort will be enrolled in Part 2 of the study to further evaluate the RPIID (approximately 20 subjects; may range from 6 to 24 subjects, depending on Part 1). If the number of subjects with confirmed CX3CR1 expression in tumor cells is below 50%, an additional 15 subjects may be included in Part 2 of the study.

开始日期2023-04-26

申办/合作机构

Novakand Pharma AB

ISRCTN18402242

/ Completed临床2期IIT

A Phase IIa, randomized, two-arm parallel-group, placebo-controlled, double-blind, multi-centre trial to evaluate the safety, tolerability, anti-inflammatory and cardio-protective effects after intravenous and oral administration of KAND567 in ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention

开始日期2021-11-15

申办/合作机构

The Newcastle upon Tyne Hospitals NHS Foundation Trust

NCT06012565

/ Terminated临床2期

KAND567 Versus Placebo in Subjects Hospitalized With COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics

The study is a phase II, randomized, 2-arm parallel-group, double-blind study to explore the efficacy, safety, tolerability and pharmacokinetics of KAND567 versus placebo in COVID-19 subjects in need of oxygen treatment.
The target was to include forty (40) subjects with diagnosed COVID-19 for participation in the study. If at screening all criteria for study participation were fulfilled and informed consent signed, the subject was enrolled and randomized into one of the two arms. After randomization, the subjects were to receive KAND567 or placebo treatment for 7 days.
After the treatment period the subjects returned to ordinary clinical follow-up, but a study follow-up visit was to be planned for Day 21 and 90.

开始日期2020-10-11

申办/合作机构

Novakand Pharma AB

100 项与 Rugocrixan 相关的临床结果

登录后查看更多信息

100 项与 Rugocrixan 相关的转化医学

登录后查看更多信息

100 项与 Rugocrixan 相关的专利（医药）

登录后查看更多信息

项与 Rugocrixan 相关的文献（医药）

2025-12-01·Food and Waterborne Parasitology

CX3CL1/CX3CR1 involved modulation of microglial activation and eosinophilic meningoencephalitis in angiostrongyliasis

Article

作者: Chen, An-Chih ; Huang, Shiang-Suo ; Wang, Yi-Hsin ; Chen, Ke-Min ; Lai, Shih-Chan ; Lu, Cheng-You

Angiostrongylus cantonensis typically infects humans through the ingestion of contaminated food or water containing the larvae. A. cantonensis is a neurotropic parasitic nematode that causes eosinophilic meningitis in humans. Upon invasion of the CNS, A. cantonensis larvae elicit a pronounced immune response, rapidly activating microglia and triggering the release of pro-inflammatory cytokines. The CX3CL1/CX3CR1 axis has been implicated in maintaining chronic microglial activation, which could exacerbate neuroinflammation. However, the precise role of this signaling pathway in angiostrongyliasis remains poorly understood. This study aims to elucidate the mechanistic role of CX3CL1/CX3CR1 signaling in microglial activation and neuronal degeneration in CNS infections caused by A. cantonensis. We analyse the expression and downstream regulatory proteins using Western blotting and evaluate neuronal degeneration by Fluoro-Jade C staining in BALB/c mice infected with A. cantonensis. Infected mice showed a marked increase in the expression of Iba-1, CX3CL1, and CX3CR1, indicative of pronounced neuroinflammation. Concurrently, infection led to elevated p-tau accumulation and reduced NeuN expression, suggesting significant neuronal damage. Pharmacological inhibition of CX3CR1 using AZD8797 mitigated these effects by downregulating CX3CL1/CX3CR1 signaling and attenuating neuronal degeneration. Further analysis revealed that the CX3CL1/CX3CR1 axis activates the Nrf2/JNK/HO-1 pathway, contributing to oxidative stress and neuroinflammatory cascades. These findings establish the CX3CL1/CX3CR1 axis as a crucial regulator of microglial activation and neuroinflammation in A. cantonensis infection. Targeting this pathway can offer a viable therapeutic strategy to mitigate inflammation of the CNS and prevent neurodegenerative consequences.

2025-09-01·MOLECULAR NEUROBIOLOGY

TREK- 1 Ameliorates Secondary Brain Injury by Regulating Inflammatory Microenvironment via CX3 CL1-CX3 CR1 Pathway After Intracerebral Hemorrhage

Article

作者: Liu, Yang ; Fang, Yongkang ; Zhu, Suiqiang ; Zhu, Zhou ; Xu, Yuan ; Zheng, Xiaolong ; Wang, Wei ; Jiang, Na ; Sadike, Dilinuer ; Wang, Yao ; Xie, Minjie ; Xu, Feng

Neuroinflammation plays a pivotal role in the pathogenesis of secondary brain injury (SBI) after intracerebral hemorrhage (ICH). TREK-1 is a background potassium channel, and its role in regulating neuroinflammation after ICH remains unclear. In this study, ICH models were induced in wide-type (WT) and TREK knockout mice via intra-striatal administration of collagenase. Additionally, WT ICH mice were treated with the TREK-1 agonist ML67-33. Immunofluorescence, western blot, quantitative real-time PCR, enzyme-linked immunosorbent assay, and RNA-sequencing were performed to determine the role and the mechanism of TREK-1 in regulating neuroinflammation after ICH. The results indicate that TREK-1 deficiency exacerbated microglia/macrophages activation and pro-inflammatory polarization, as well as the influx of inflammatory cytokines and peripheral inflammatory cells compared to WT ICH mice. Conversely, activation of TREK-1 attenuated the inflammatory response and SBI post-ICH. These effects may be mediated through the CX3CL1-CX3CR1 pathway, as validated by specific inhibitors AZD8797. This study identified TREK-1 as a crucial modulator in alleviating SBI by regulating the inflammatory microenvironment via the CX3CL1-CX3CR1 pathway.

2025-03-01·JOURNAL OF NEUROCHEMISTRY

Upregulation of Cathepsin S Expression Contributes to Neuronal Damage Following Kainic Acid–Induced Status Epilepticus

Article

作者: Chang, Jang‐Yang ; Chen, Chin‐Hao ; Hsu, Kuei‐Sen ; Cheng, Kuan‐Hsiang ; Shih, Hsin‐Ling

ABSTRACT:

Status epilepticus (SE) is a life‐threatening neurological emergency characterized by persistent seizures, leading to brain damage that increases the risk of recurrent seizures due to abnormal electrical impulses produced by damaged neurons. However, the molecular mechanism by which convulsive SE leads to neuronal damage is not completely understood. Cathepsin S (Ctss), a lysosomal cysteine protease, has been implicated in secondary injury after traumatic brain injury. This study sought to explore whether Ctss is also involved in SE‐induced neuronal damage in the hippocampus. Immunohistochemistry and Western blotting were utilized to detect the expression of Ctss in the hippocampal subregions of male C57BL/6J mice at various times following kainic acid (KA)–induced SE. The reactivity of microglia was assessed using immunohistochemistry, and Fluoro‐Jade C (FJC) staining was employed to identify damaged neurons. We found that the mature form of Ctss is barely observed in naïve adult (12‐week‐old) mouse hippocampus, but its expression is significantly evident at 50 weeks of age. In adult mice, the expression of both pro‐and mature forms of Ctss in the hippocampal CA3 region was increased as early as 16 h following KA‐induced SE. The increased Ctss immunoreactivity was mainly found in microglia following KA‐induced SE. The damaged neurons visualized by FJC staining were prominent in the CA3 region at 16 h following KA‐induced SE. Ctss knockdown did not affect KA‐induced behavioral seizures but significantly reduced SE‐induced microglia activation and neuronal damage. An increase in chemokine CX3C motif ligand 1 (CX3CL1) immunoreactivity on microglia was observed following KA‐induced SE, and CX3C motif chemokine receptor 1 (CX3CR1) antagonist AZD8797 treatment significantly attenuated SE‐induced microglia activation and neuronal damage. Altogether, these results indicate a crucial role of Ctss in SE‐induced neuronal damage, possibly through CXC3L1‐mediated microglial activation, and provide a new perspective for preventing SE‐induced neuronal damage.image

项与 Rugocrixan 相关的新闻（医药）

2026-02-10

·FierceBiotech

AstraZeneca relaxed about relaxin drug\'s poor efficacy in phase 2 heart failure trial

AstraZeneca shared news it cut AZD3427 from its pipeline alongside the removal of two other new molecular entities.\n AstraZeneca executives have told Fierce Biotech they still see potential in harnessing the relaxin hormone to treat heart failure despite abandoning work on one of two clinical-stage candidates. As part of its full-year 2025 financial results (PDF), the U.K.-based Big Pharma revealed that it removed a long-acting relaxin-2 analog called AZD3427 from its pipeline, citing underwhelming efficacy in a phase 2 trial.There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s vasodilatory, anti‐inflammatory and antifibrotic effects has yet to translate into clinical success.AstraZeneca identified the short half-lives of earlier candidates as a potential cause of the failures. To fix the problem, the company created a relaxin-2 mimic fusion protein and attached a fragment to create a candidate with a half-life measured in days rather than hours. However, AstraZeneca has now stopped development of AZD3427 after completing a phase 2 trial in 260 people with heart failure. While AZD3427 has been sunk by efficacy, the company is continuing to develop the oral relaxin drug candidate AZD5462. AstraZeneca has called (PDF) the candidate the first small molecule targeting relaxin biology to enter clinical trials. Data from a phase 2b trial of stable patients with chronic heart failure are due in the second half of 2026.During a press conference this morning, Sharon Barr, Ph.D., executive vice president of biopharmaceuticals R&D at AstraZeneca, told Fierce the company is moving forward with AZD5462 “because we think this is a potentially important molecule.”“One of the things that we have learned from competitor studies is that dosing matters,” Barr continued. “You really have to find that perfect space between efficacy and congestion, and we think we\'ve put in the hard yards to really understand the posology there, and we\'re moving forward with our existing program.”AstraZeneca CEO Pascal Soriot also told Fierce during the call that work on the relaxin program is a case study of “what is so exciting in this industry at this present time.”Soriot pointed to the likes of ACE inhibitors and SGLT2 drugs as examples of the progress made in recent years to treat specific groups of cardiovascular patients.“There\'s more and more of those technologies, and we need just to pick the right products to really help patients with heart disease,” the CEO added. AstraZeneca disclosed its discontinuation of AZD3427 alongside the removal of two other new molecular entities from the pipeline. The drugmaker confirmed the removal of AZD0233, a CX3CR1 modulator that was in development as a treatment for dilated cardiomyopathy. AstraZeneca terminated a phase 1 trial of the candidate last month over an adverse finding in a nonclinical, chronic toxicology study.The company also revealed it had axed a COVID-19 vaccine program. AstraZeneca moved the mRNA viruslike particle vaccine program into phase 1 in late 2023. Recently, the company reported that a vaccine candidate was well tolerated compared to Pfizer and BioNTech’s Comirnaty and generated similar immunogenicity at one-third of the dosage.

$AstraZeneca relaxed about relaxin drug\'s poor efficacy in phase 2 heart failure trial$

疫苗临床2期临床1期财报

2025-10-09

·novakand.com

Novakand Pharma provides an update on the ongoing reverse take over process

On September 18, 2025 Novakand Pharma AB (publ) announced that the board had decided to initiate a process to identify potential stakeholders for a reverse take over. The company now reports that discussions are initiated with Swedish un-listed growth companies, both within and outside the life science sector, and that parallel discussions concerning a potential divestment of the fractalkine program are being held. In addition, cost reduction activities have been implemented. Discussions concerning a reverse take over Novakand Pharma has initiated concrete discussions with potential target companies for a reverse take over. Novakand is discussing the potential reverse take over with Swedish un-listed growth companies aiming to be listed at the Nasdaq First North and are both in and outside the life science sector. Divestment of the fractalkine program In parallel, the work with divesting or transferring the fractalkine program and the candidate drugs rugocrixan and fosrugocrixan is ongoing. Considering that the company for several years conducted extensive business development without being successful in entering into licensing agreements, and that significant investments in clinical development and manufacturing are required to advance the program, the probability of closing a transaction is perceived to be low. The board emphasizes that currently there is no guarantee that a divestment or transfer will occur, but if this happens, the assessment is that the acquirer will not be a big pharma, but rather a smaller company and that any purchase price would likely be limited. Reduction of the company’s operational expences Cost reduction activities have been implemented in a number of areas, including the company’s organization. Decisions and next steps The board is now evaluating the ongoing discussions concerning a potential reverse take over and potential divestment of the fractalkine program, in relation to the alternative to liquidize the company. The board emphasizes that currently there is no guarantee that a transaction – either a reverse take over or a divestment of assets – will be conducted. In the event that, after a reasonable time has passed, strategic options are missing, the board’s intention is to recommend a de-listing from the Nasdaq First North Growth Market and a voluntary liquidation of the company, by which available cash will be distributed to current shareholders. A decision to execute a potential reverse take over, de-listing or liquidation of the company will be taken by the shareholders at a future general meeting. A potential reverse take over will also be subject to a new approved listing review by Nasdaq.The board will continue to update the market concerning significant events during the process. ”We have now started the announced process and are engaged in concrete discussions with several growth companies that see a value in Novakand Pharma’s listing. Our intention is to conduct this process as efficiently as possible in order to be able to present a proposal to our shareholders soon,” says Erik Nerpin, chairman of the board at Novakand Pharma. About Novakand Pharma AB Novakand Pharma is a clinical stage biotech developing a new class of small molecule drugs with an immune cell modulating mode-of-action. The stock is traded on the Nasdaq First North Premier Growth Market. Redeye AB is the company’s Certified Adviser and can be contacted at: certifiedadviser@redeye.se. For further information: Visit the company’s website at: www.novakand.com or contact: ir@novakand.com or +46 (0)8-5012 60 80. Attachments PR EN RTO Update 251009

并购

2023-01-26

·PRNewswire

Myocardial Infarction (MI) Market is Projected to Grow at a Minimal CAGR of 1.61% During the Study Period (2019-2032) | Assesses DelveInsight

Considering the expected launch of new upcoming therapies and greater integration of early patient screening, it can be safely assumed that the MI market will undergo a paradigm shift in the present decade holding new prospects and opportunities for those planning to carve out their niche during the forecast period [2022–2032] LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's MI Market Insights report includes a comprehensive understanding of current treatment practices, MI emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Key Takeaways from the MI Market Report As per DelveInsight analysis, the MI market size in the 7MM was approximately USD 21 billion in 2021 According to the assessment done by DelveInsight, the estimated total MI diagnosed prevalent cases in the 7MM was approximately 15 million in 2021 Leading MI companies such as AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and others are developing novel MI drugs that can be available in the MI market in the coming years The promising MI therapies in the pipeline include FARXIGA/FORXIGA (dapagliflozin), JARDIANCE (empagliflozin), Olpasiran (AMG860), Pelacarsen (TQJ230), Selatogrel, FDY-5301, CSL112, IMT-358, CL2020, MEDI6570, KAND567, Asundexian, Dutogliptin, MPC-25-IC , and others In November 2022, Amgen presented end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions and simultaneously published in the New England Journal of Medicine As per the Q32022 investor presentation of AstraZeneca data, readouts from the Phase III (DAPA-MI) trial of FARXIGA/FORXIGA is anticipated by 2H 2023. With an estimated key regulatory submission acceptance after 2023 In June 2021, Idorsia announced the initiation of the Phase III registration study "SOS-AMI" to evaluate the efficacy and safety of self-administered SC selatogrel in suspected AMI In September 2020, the FDA granted Fast Track designation for the development of JARDIANCE to prevent hospitalization for heart failure and reduce the risk of mortality in patients with and without diabetes who have had an acute MI In July 2020, AstraZeneca was granted Fast Track designation in the US for the development of FARXIGA to reduce the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults following an AMI or heart attack Discover which therapies are expected to grab the major MI market share @ MI Market Report. MI Overview MI is pathologically defined as myocardial cell death caused by prolonged ischemia. The first ultrastructural changes are diminished cellular glycogen, relaxed myofibrils, and sarcolemmal disruption, which can be seen as early as 10-15 minutes after the onset of ischemia. Symptoms of MI include chest pain, which may initially manifest as a sensation of tightness or pressure. The pain usually radiates to the left arm, but it can also radiate to the lower jaw, neck, right arm, back, and upper abdomen. Sweating, nausea, vomiting, and fainting may accompany chest pain. The typical clinical features, ECG findings, and elevation of cardiac biomarkers are used for MI diagnosis. Cardiovascular catheterization is required for definitive diagnosis and serves diagnostic and therapeutic purposes. All patients suspected of having ACS should be considered for emergency revascularization; other MI treatment options include anticoagulation, antiplatelet therapy, statin therapy, and other adjunctive measures. MI Epidemiology Segmentation DelveInsight estimates that there were approximately 15 million diagnosed prevalent cases of MI in the 7MM in 2021. Among EU4 countries, Germany had the highest number of diagnosed prevalent cases of MI, while Spain had the lowest prevalent population among the 7MM. The MI market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Diagnosed Prevalent Cases Gender-specific Prevalence Type-specific Prevalence Download the report to understand which factors are driving MI epidemiology trends @ MI Epidemiological Insights. MI Treatment Market The goals of initial MI treatment are to relieve pain, immediately identify ST changes via 12-lead EKG, initiate reperfusion (if the patient is a candidate), and assess and treat hemodynamic abnormalities. Oxygen, nitroglycerin, and morphine sulfate are the most effective pain relievers. Reperfusion therapy is indicated for patients with ST-segment elevation or a new LBBB with symptoms lasting 12 hours or less. MI treatment may be divided into two paths depending on whether the patient has a STEMI or an NSTEMI. The pharmacologic MI treatment is further subdivided into several groups of medications that improve survival, reduce recurrent ischemic events, and provide symptomatic relief. Following the primary MI treatment, a multimodal regimen of therapies is used. To classify the disease, rapid diagnostic tests and serial biomarker analysis are used to begin MI treatment. The current MI market has been segmented into different commonly used therapeutic classes based on the prevailing MI treatment pattern across the 7MM, which exhibits minor variations in the overall prescription pattern. The major classes covered in the forecast model are antiplatelet agents, anticoagulants, vasodilators, beta-blockers, lipid-lowering drugs, Angiotensin-converting enzyme (ACE) inhibitors, ARBs (Angiotensin-II receptor Blockers), and calcium channel blockers. In recent years, it has been demonstrated that pre-hospital thrombolysis has a role in the management of patients seen early after symptom onset in comparison/association with patients who had primary coronary intervention or elective primary coronary intervention. This is an important issue that is still being researched to prevent cardiac arrest, large scares, and again limit the transition to heart failure and improve the survival rate after AMI. To know more about MI treatment guidelines, visit @ MI Management. MI Pipeline Therapies and Key Companies FARXIGA/FORXIGA (dapagliflozin): AstraZeneca JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company Pelacarsen (TQJ230): Novartis Olpasiran: Amgen Selatogrel: Idorsia Pharmaceuticals FDY-5301: Faraday Pharmaceuticals CSL112: CSL Behring IMT-358: Immediate Therapeutics CL2020: Mitsubishi Chemical Group MEDI6570: AstraZeneca KAND567: Kancera Asundexian: Bayer Dutogliptin: Recardio MPC-25-IC: Mesoblast Learn more about the FDA-approved drugs for MI @ Drugs for MI Treatment. MI Market Dynamics The dynamics of MI market is anticipated to change in the coming years. The growing emphasis on secondary preventive measures to avoid recurrent/new events, lifestyle changes, and the growing number of smokers and cases of obesity, diabetes, hypertension, and others, are expected to fuel MI market growth. Moreover, heart attacks and strokes are major cost drivers in the 7MM healthcare system. The volume of the MI market is enormous. The patient is receiving multiple therapies at the same time. The smallest portion of the patient share can provide pharmaceutical companies with options worth millions of dollars in the MI market. However, several factors are likely to affect the growth of the MI market. Women appear to be underdiagnosed with MI, despite being at higher risk because medical training for healthcare professionals and public information has emphasized the identification of symptoms that typically affect men. This highlights the importance of gender differences in developing strategies for early MI detection and tailored secondary prevention after MI, which should result in a higher rate of MI detection in women. Moreover, off-label therapies and generics account for the majority of the current MI market because they are less expensive and more easily accessible to patients, thus, causing a dip in the MI market growth. Hence, all these factors mentioned above will hamper the MI market growth in the future. Scope of the MI Market Report Therapeutic Assessment: MI current marketed and emerging therapies MI Market Dynamics: MI market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, MI Market Access and Reimbursement Discover more about MI drugs in development @ MI Clinical Trials. Table of Contents Related Reports MI Pipeline MI Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key MI companies, including CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, among others. MI Epidemiology Forecast MI Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted MI epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Myocarditis Pipeline Myocarditis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myocarditis companies, including Cantargia AB, Cardiol Therapeutics, Apitope, among others. Dilated Cardiomyopathy Pipeline Dilated Cardiomyopathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dilated cardiomyopathy companies, including Longeveron, Bristol Myers Squibb, Berlin Cures, Tenaya Therapeutics, Cardior Pharmaceuticals, among others. Cardiac Biomarkers Testing Market Cardiac Biomarkers Testing Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cardiac biomarkers testing companies, including Beckman Coulter, Inc, Siemens Healthcare GmbH, Abbott, among others. Dilated Cardiomyopathy Epidemiology Dilated Cardiomyopathy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted dilated cardiomyopathy epidemiology in the 7MM. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Blogs Upcoming Cardiovascular Diseases Drugs Key Companies in the Cardiology Segment Heart Failure Market Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on: LinkedIn | Facebook | Twitter. Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services. Logo - Contact Us: Shruti Thakur [email protected] +1(919)321-6187 SOURCE DelveInsight Business Research, LLP

临床3期快速通道

100 项与 Rugocrixan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
输卵管癌	临床2期	丹麦	Novakand Pharma AB	2023-04-26
输卵管癌	临床2期	挪威	Novakand Pharma AB	2023-04-26
输卵管癌	临床2期	瑞典	Novakand Pharma AB	2023-04-26
卵巢上皮癌	临床2期	丹麦	Novakand Pharma AB	2023-04-26
卵巢上皮癌	临床2期	挪威	Novakand Pharma AB	2023-04-26
卵巢上皮癌	临床2期	瑞典	Novakand Pharma AB	2023-04-26
复发性铂耐药性原发性腹膜癌	临床2期	丹麦	Novakand Pharma AB	2023-04-26
复发性铂耐药性原发性腹膜癌	临床2期	挪威	Novakand Pharma AB	2023-04-26
复发性铂耐药性原发性腹膜癌	临床2期	瑞典	Novakand Pharma AB	2023-04-26
急性心肌梗塞	临床2期	英国	Novakand Pharma AB	2021-11-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


FRACTAL (ESC2024)	临床2期	急性心肌梗塞 fractalkine receptor CX3CR1	71	KAND567	選鏇壓構糧鹽襯憲廠鑰(願選壓糧廠壓範齋鏇構) = Throughout the 3-month follow-up period, 23 (62%) patients from the KAND567 arm as compared to 24 (71%) patients in the placebo arm had reported adverse events. 鑰構願衊廠蓋範鑰齋遞 (構願觸獵窪壓鹽簾衊襯 ) 更多	积极	2024-09-02
				Placebo
FRACTAL (ESC2024)	临床2期	急性心肌梗塞 troponin	71	KAND567	糧鑰鬱衊夢壓鹹膚壓醖(餘齋淵齋範遞鹹糧築壓) = 糧膚鏇醖衊築構襯憲膚觸衊衊繭糧遞衊窪壓艱 (鏇鬱淵構網窪網衊廠範 )	积极	2024-09-01
				Placebo	糧鑰鬱衊夢壓鹹膚壓醖(餘齋淵齋範遞鹹糧築壓) = 鬱膚淵簾製壓糧廠膚憲觸衊衊繭糧遞衊窪壓艱 (鏇鬱淵構網窪網衊廠範 )
ISRCTN18402242 (FRACTAL, NEWS)	临床2期	ST段抬高心肌梗死	71	KAND 567	鏇襯願糧築築壓憲鑰廠(繭憲憲選築淵壓簾鏇襯) = 壓夢築齋夢窪願積範蓋願鑰齋壓壓鹹網願餘築 (膚獵膚構膚繭觸糧窪鹽 ) 更多	积极	2024-02-06
				安慰剂	窪範鏇壓衊壓衊餘壓齋(衊廠獵鑰淵鹽簾淵鑰顧) = 築蓋糧簾遞蓋簾廠簾壓齋簾餘積窪膚淵鏇壓艱 (窪蓋艱壓齋淵網糧壓簾 )